专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080305076A1 METHOD OF INDUCING MEMORY B CELL DEVELOPMENT AND TERMINAL DIFFERENTIATION 有权
标题翻译：诱导记忆B细胞发育和终末分化的方法
公开(公告)号：US20080305076A1
公开(公告)日：2008-12-11
申请号：US12126166
申请日：2008-05-23
申请人： Catherine Rachel Ettinger , Peter E. Lipsky , Warren J. Leonard , Rosanne Spolski , Herbert C. Morse, III
发明人： Catherine Rachel Ettinger , Peter E. Lipsky , Warren J. Leonard , Rosanne Spolski , Herbert C. Morse, III
IPC分类号： A61K38/20 , C12Q1/02 , C40B30/06 , A61K48/00 , A61K31/711 , G01N33/567 , C12N5/06
CPC分类号： G01N33/5052 , A61K35/17 , A61K38/20 , A61K2035/124 , A61K2039/5158 , C12N5/0635 , C12N2501/052 , C12N2501/23 , C12N2501/50 , C12N2501/52 , G01N2333/54
摘要： A method is disclosed herein for inducing differentiation of a B cell progenitor into a memory B cells and/or a plasma cell. The method includes contacting a population of cells including a mature B cell or a B cell progenitor with an effective amount of IL-21, and isolating memory B cells or plasma cells. In one embodiment, the B cell progenitor is an immature B cell. A method is also disclosed for enhancing an immune response. The method includes contacting a population of cells including a B cell progenitor with an effective amount of IL-21, and isolating memory B cells or plasma cells. The memory B cells and/or the plasma cell are then introduced into the subject to enhance the immune response. A method is also disclosed for treating a subject with a condition comprising a specific deficiency of at least one of memory B cells and plasma cells. A method is disclosed for identifying an agent with a physiological effect on one or more of a memory B cell and a plasma cell differentiation. A method is also disclosed for identifying agents that inhibit an activity of IL-21. Methods are also disclosed for inducing apoptosis of a B cell and for decreasing the number of B cells. A method is also described for producing a B cell hybridoma.
摘要翻译：本文公开了一种用于诱导B细胞祖细胞分化为记忆B细胞和/或浆细胞的方法。该方法包括使包含成熟B细胞或B细胞祖细胞的细胞群与有效量的IL-21接触，并分离记忆B细胞或浆细胞。在一个实施方案中，B细胞祖细胞是未成熟B细胞。还公开了一种用于增强免疫应答的方法。该方法包括使包含B细胞祖细胞的细胞群与有效量的IL-21接触，并分离记忆B细胞或浆细胞。然后将记忆B细胞和/或浆细胞引入受试者以增强免疫应答。还公开了一种用于治疗患有包含存储B细胞和浆细胞中的至少一种的特定缺陷的病症的受试者的方法。公开了用于鉴定对存储B细胞和浆细胞分化中的一种或多种具有生理作用的药剂的方法。还公开了用于鉴定抑制IL-21活性的试剂的方法。还公开了诱导B细胞凋亡和减少B细胞数量的方法。还描述了用于产生B细胞杂交瘤的方法。

2. 发明授权

US07378276B2 Method of inducing memory B cell development and terminal differentiation 有权
标题翻译：诱导记忆B细胞发育和终末分化的方法
公开(公告)号：US07378276B2
公开(公告)日：2008-05-27
申请号：US11197221
申请日：2005-08-03
申请人： Catherine Rachel Ettinger , Peter E. Lipsky , Warren J. Leonard , Rosanne Spolski , Herbert C. Morse, III
发明人： Catherine Rachel Ettinger , Peter E. Lipsky , Warren J. Leonard , Rosanne Spolski , Herbert C. Morse, III
IPC分类号： C12N5/02 , C12N5/08 , A01N37/18 , C07K1/00
CPC分类号： G01N33/5052 , A61K35/17 , A61K38/20 , A61K2035/124 , A61K2039/5158 , C12N5/0635 , C12N2501/052 , C12N2501/23 , C12N2501/50 , C12N2501/52 , G01N2333/54
摘要： A method is disclosed herein for inducing differentiation of a B cell progenitor into a memory B cells and/or a plasma cell. The method includes contacting a population of cells including a mature B cell or a B cell progenitor with an effective amount of IL-21, and isolating memory B cells or plasma cells. In one embodiment, the B cell progenitor is an immature B cell. A method is also disclosed for enhancing an immune response. The method includes contacting a population of cells including a B cell progenitor with an effective amount of IL-21, and isolating memory B cells or plasma cells. The memory B cells and/or the plasma cell are then introduced into the subject to enhance the immune response. A method is also disclosed for treating a subject with a condition comprising a specific deficiency of at least one of memory B cells and plasma cells. A method is disclosed for identifying an agent with a physiological effect on one or more of a memory B cell and a plasma cell differentiation. A method is also disclosed for identifying agents that inhibit an activity of IL-21. Methods are also disclosed for inducing apoptosis of a B cell and for decreasing the number of B cells. A method is also described for producing a B cell hybridoma.
摘要翻译：本文公开了一种用于诱导B细胞祖细胞分化为记忆B细胞和/或浆细胞的方法。该方法包括使包含成熟B细胞或B细胞祖细胞的细胞群与有效量的IL-21接触，并分离记忆B细胞或浆细胞。在一个实施方案中，B细胞祖细胞是未成熟的B细胞。还公开了一种用于增强免疫应答的方法。该方法包括使包含B细胞祖细胞的细胞群与有效量的IL-21接触，并分离记忆B细胞或浆细胞。然后将记忆B细胞和/或浆细胞引入受试者以增强免疫应答。还公开了一种用于治疗患有包含存储B细胞和浆细胞中的至少一种的特定缺陷的病症的受试者的方法。公开了用于鉴定对存储B细胞和浆细胞分化中的一种或多种具有生理作用的药剂的方法。还公开了用于鉴定抑制IL-21活性的试剂的方法。还公开了诱导B细胞凋亡和减少B细胞数量的方法。还描述了用于产生B细胞杂交瘤的方法。

3. 发明授权

US08247228B2 Method of inducing memory B cell development and terminal differentiation 有权
标题翻译：诱导记忆B细胞发育和终末分化的方法
公开(公告)号：US08247228B2
公开(公告)日：2012-08-21
申请号：US12126166
申请日：2008-05-23
申请人： Catherine Rachel Ettinger , Peter E. Lipsky , Warren J. Leonard , Rosanne Spolski , Herbert C. Morse, III
发明人： Catherine Rachel Ettinger , Peter E. Lipsky , Warren J. Leonard , Rosanne Spolski , Herbert C. Morse, III
IPC分类号： C12N5/00 , C12N5/07
CPC分类号： G01N33/5052 , A61K35/17 , A61K38/20 , A61K2035/124 , A61K2039/5158 , C12N5/0635 , C12N2501/052 , C12N2501/23 , C12N2501/50 , C12N2501/52 , G01N2333/54
摘要： The invention provides a method for promoting differentiation of a mature naïve B cell or a B cell progenitor into a memory B cell or a plasma cell. The method comprises (a) contacting a population of cells comprising a mature naïve B cell or a B cell progenitor with an agent that activates at least one of JAK1, JAK3, STAT3, STAT5A or STAT5B; wherein the population of cells optionally is contacted with an antigen, and (b) isolating the memory B cell or plasma cell.
摘要翻译：本发明提供了促进成熟初始B细胞或B细胞祖细胞分化成记忆B细胞或浆细胞的方法。该方法包括（a）使包含成熟初始B细胞或B细胞祖细胞的细胞群与活化JAK1，JAK3，STAT3，STAT5A或STAT5B中的至少一种的药剂接触; 其中细胞群任选地与抗原接触，和（b）分离记忆B细胞或浆细胞。

4. 发明申请

US20080166338A1 IL-21 AS A REGULATOR OF IMMUNOGLOBIN PRODUCTION 审中-公开
标题翻译： IL-21作为免疫球蛋白生产的调节剂
公开(公告)号：US20080166338A1
公开(公告)日：2008-07-10
申请号：US11958540
申请日：2007-12-18
申请人： Warren J. Leonard , Katsutoshi Ozaki , Rosanne Spolski , Herbert C. Morse , Peter E. Lipsky , Derry Roopenian
发明人： Warren J. Leonard , Katsutoshi Ozaki , Rosanne Spolski , Herbert C. Morse , Peter E. Lipsky , Derry Roopenian
IPC分类号： A61K39/395 , A61P43/00
CPC分类号： C07K14/7155 , A01K67/0276 , A01K2217/05 , A01K2227/105 , A01K2267/0381 , C07K14/5406 , C12N15/8509
摘要： A transgenic mouse is disclosed herein whose somatic and germ cells comprise a disrupted IL-21 receptor gene, the disruption being sufficient to inhibit the binding of IL-21 to an IL-21 receptor, and a disrupted IL-4 gene, the disruption being sufficient to inhibit the production of IL-4 or the binding of IL-4 to the IL-4 receptor. A mouse homozygous for the disrupted IL-21 receptor gene and homozygous for the disrupted IL-4 gene has diminished B cell function. A method is disclosed for altering a B cell activity. The method includes administering a therapeutically effective amount of an agent that interferes with the interaction of IL-21 with an IL-21 receptor, thereby altering the B cell activity. A method is also disclosed for of treating a subject with Job's disorder or atopic disease. A method is also disclosed for treating or preventing an allergic reaction in a subject. A method is also disclosed for treating a subject with an autoimmune or antibody mediated disorder.
摘要翻译：本文公开了一种转基因小鼠，其体细胞和生殖细胞包含破坏的IL-21受体基因，所述破坏足以抑制IL-21与IL-21受体的结合以及破坏的IL-4基因，所述破坏是足以抑制IL-4的产生或IL-4与IL-4受体的结合。对于破坏的IL-21受体基因纯合的小鼠和破坏的IL-4基因是纯合的，具有减少的B细胞功能。公开了用于改变B细胞活性的方法。该方法包括施用治疗有效量的干扰IL-21与IL-21受体相互作用的试剂，由此改变B细胞活性。还公开了用于治疗患有约瑟病或特应性疾病的受试者的方法。还公开了用于治疗或预防受试者的过敏反应的方法。还公开了用自身免疫或抗体介导的病症治疗受试者的方法。

5. 发明授权

US5846742A Selecting substances for treating glucocorticoid-mediated inflammation or immune diseases using Tripterygium wilfordii Hook F extracts 失效
标题翻译：选择使用雷公藤钩藤F提取物治疗糖皮质激素介导的炎症或免疫疾病的物质
公开(公告)号：US5846742A
公开(公告)日：1998-12-08
申请号：US800867
申请日：1997-02-14
申请人： Peter E. Lipsky , Xue-Lian Tao , Jian Cai , William J. Kovacs , Nancy J. Olson
发明人： Peter E. Lipsky , Xue-Lian Tao , Jian Cai , William J. Kovacs , Nancy J. Olson
IPC分类号： A61K31/365 , A61K31/44 , A61K31/565 , A61K31/74 , A61K36/00 , A61K36/37 , C12Q1/00 , G01N33/566 , C12N5/00 , C12Q1/48 , C12Q1/66
CPC分类号： A61K31/565 , A61K31/365 , A61K31/44 , A61K36/37 , Y10S514/821 , Y10S514/825 , Y10S514/886
摘要： The present invention provides for the use of Tripterygium wilfordii Hook F extracts and purified components thereof in the treatment of inflammation or an immune disorder with concomitant lack of steroidal effect. Extracts of this plant (T2) bound to the glucocorticoid receptor and competitively inhibited glucocorticoid mediated cellular processes, such as dexamethasone binding to the glucocorticoid receptor, glucocorticoid mediated activation of target genes, dexamethasone dependent cellular growth, with concomitant inhibition of cyclooxygenase-2 induction and inflammatory processes such as the production of prostaglandin E.sub.2. The T2 extract components triptolide and tripdiolide were effective inhibitors. The particular advantage provided by the methods herein is the treatment or prevention of inflammation and the concomitant lack of steroidal agonist effects and NSAID side effects. Conditions treatable by the present methods include inflammation and immune disorders including autoimmune disease.
摘要翻译：本发明提供了雷公藤提取物及其纯化组分用于治疗炎症或免疫疾病以及伴随的缺乏类固醇效应的用途。该植物（T2）的提取物与糖皮质激素受体结合，并且竞争性抑制糖皮质激素介导的细胞过程，例如与糖皮质激素受体结合的地塞米松，糖皮质激素介导的靶基因活化，地塞米松依赖性细胞生长，伴随环氧合酶-2诱导的抑制; 炎症过程如前列腺素E2的产生。 T2提取物组分雷公藤内酯和tripdiolide是有效的抑制剂。本文方法提供的特别的优点是治疗或预防炎症和伴随的缺乏甾体激动剂效应和NSAID副作用。通过本发明方法可治疗的病症包括炎症和免疫疾病，包括自身免疫性疾病。

6. 发明授权

US5068223A Hydrophobic peptide esters and amides 失效
标题翻译：疏水肽类和酰胺类
公开(公告)号：US5068223A
公开(公告)日：1991-11-26
申请号：US324151
申请日：1989-03-15
申请人： Peter E. Lipsky , Dwain L. Thiele
发明人： Peter E. Lipsky , Dwain L. Thiele
IPC分类号： A61K38/05
CPC分类号： A61K38/05
摘要： Esters or amides of a peptide, preferebly a dipeptide, consisting essentially of natural or synthetic L-amino acids with hydrophobic side chains were found to have specific cellular toxicities. Preferable amino acids of the peptide are leucine, phenylalanine valine, isoleucine, alanine, proline, glycine or aspartic acid beta methyl ester. Preferable dipeptides are L leucyl L-leucine, L-leucyl L-phenylalanine, L-valyl L-phenylalanine, L-Leucyl L-isoleucine, L-henylalanyl L-phenylalanine, L-valyl L-leucine, L-leucyl L-alanine, L-valyl L-valine, L-phenylalanyl L leucine, L prolyl L-leucine, L-leucyl L-valine, L-phenylalanyl L-valine, L glycyl L-leucine, L-leucyl L-glycine, glycyl L-phenylalanine and L-aspartyl beta methyl ester L-phenylalanine. Most preferable dipeptides are L-leucyl L-leucine, L-leucyl L-phenylalanine, L-valyl L-phenylalanine, L-phenylalanyl L-leucine, L-leucyl L-isoleucine L-phenylalanyl L-phenylalanine and L-valyl L-leucine.The ester or amide of the dipeptide is most preferably alkyl, aralkyl or aryl a preferred alkylester is a methyl ester and may also be an ethyl ester or alkyl of up to about four carbon atoms such as propyl, isopropyl, butyl or isobutyl. Yet larger alkyl substituents may also be functional judging from the beta naphthyl substituent which is functional in certain embodiments.These alkyl, aryl or arylkyl esters and amides of dipeptides consist essentially of amino acids with hydrophobic side chains may be used to deplete cytotoxic T-lymphocytes or natural killer cells from organisms, cell populations or tissues.
摘要翻译：被发现具有疏水侧链的天然或合成的L-氨基酸的肽，优先二肽的酯或酰胺具有特异性的细胞毒性。肽的优选氨基酸是亮氨酸，苯丙氨酸缬氨酸，异亮氨酸，丙氨酸，脯氨酸，甘氨酸或天冬氨酸β-甲酯。优选的二肽是L-亮氨酸L-亮氨酸，L-亮氨酰L-苯丙氨酸，L-缬氨酰L-苯丙氨酸，L-亮氨酰L-异亮氨酸，L-苯丙氨酰丙氨酰L-苯丙氨酸，L-缬氨酰L-亮氨酸，L-亮氨酰L-丙氨酸，L-缬氨酰L-缬氨酸，L-苯丙氨酰L-亮氨酸，L脯氨酰L-亮氨酸，L-亮氨酰L-缬氨酸，L-苯丙氨酰L-缬氨酸，L-甘氨酰L-亮氨酸，L-亮氨酰L-甘氨酸，苯丙氨酸和L-天冬氨酰基β-甲酯L-苯丙氨酸。最优选的二肽是L-亮氨酸L-亮氨酸，L-亮氨酰L-苯丙氨酸，L-缬氨酰L-苯丙氨酸，L-苯丙氨酰L-亮氨酸，L-亮氨酰L-异亮氨酸L-苯丙氨酰L-苯丙氨酸和L-缬氨酰L- 亮氨酸。二肽的酯或酰胺最优选是烷基，芳烷基或芳基，优选的烷基酯是甲酯，也可以是最多约四个碳原子的乙酯或烷基，如丙基，异丙基，丁基或异丁基。根据在某些实施方案中是功能的β萘基取代基，更大的烷基取代基也可以是官能的。这些二肽的烷基，芳基或芳基烷基酯和酰胺基本上由具有疏水侧链的氨基酸组成可用于从生物体，细胞群或组织中消耗细胞毒性T淋巴细胞或天然杀伤细胞。

7. 发明申请

US20090148843A1 Means and Methods for the Prediction of Joint Destruction 审中-公开
标题翻译：联合破坏预测手段和方法
公开(公告)号：US20090148843A1
公开(公告)日：2009-06-11
申请号：US12089843
申请日：2006-10-12
申请人： Hendrik Schulze-Koops , Alla Skapenko , Peter E. Lipsky
发明人： Hendrik Schulze-Koops , Alla Skapenko , Peter E. Lipsky
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/158
摘要： The present invention relates to a method of diagnosing and/or predicting joint destruction, early joint destruction and/or accelerated joint destruction in particular, in rheumatoid arthritis, comprising determining in a sample obtained from an individual the presence of at least one nucleic acid sequence encoding an IL-4 receptor (IL-4R) which contains a mutation in position 465 of the nucleotide sequence of the wild-type IL4R as shown in SEQ ID NO: 1, whereby at said position the nucleotide A is replaced or a nucleic acid sequence encoding an IL-4 receptor (IL-4R), said IL-4R comprising at position 75 as shown in SEQ ID NO: 2 a valine instead of an isoleucine. Furthermore, the invention provides for a method of diagnosing and/or predicting early joint destruction and/or accelerated joint destruction comprising determining in a sample obtained from an individual the presence of an encoded IL-4 receptor (IL-4R) which comprises at the homologous position 75 of IL-4 receptor as depicted in SEQ ID NO: 2 a mutation, said mutation comprising the exchange from an isoleucine to a valine. In addition, the present invention relates to a use of specific probes and/or primers for the preparation of a diagnostic composition for diagnosing and/or predicting early joint destruction and/or accelerated joint destruction in particular in rheumatoid arthritis.
摘要翻译：本发明涉及诊断和/或预测关节破坏，早期关节破坏和/或加速联合破坏，特别是在类风湿性关节炎中的方法，包括在从个体获得的样品中确定存在至少一个核酸序列编码如SEQ ID NO：1所示的野生型IL4R的核苷酸序列的位置465的突变的IL-4受体（IL-4R），由此在所述位置替换核苷酸A或核酸编码IL-4受体（IL-4R）的序列，所述IL-4R在SEQ ID NO：2所示的位置75包含缬氨酸而不是异亮氨酸。此外，本发明提供了诊断和/或预测早期关节破坏和/或加速关节破坏的方法，包括在从个体获得的样品中确定存在编码的IL-4受体（IL-4R），其包含在如SEQ ID NO：2所示的IL-4受体的同源位置75是突变，所述突变包括从异亮氨酸到缬氨酸的交换。此外，本发明涉及特异性探针和/或引物用于制备用于诊断和/或预测早期关节破坏和/或加速联合破坏，特别是在类风湿性关节炎中的诊断组合物的用途。

8. 发明授权

US5668112A Hydrophobic peptide esters and amides 失效
标题翻译：疏水肽类和酰胺类
公开(公告)号：US5668112A
公开(公告)日：1997-09-16
申请号：US310677
申请日：1994-09-22
申请人： Peter E. Lipsky , Dwain L. Thiele
发明人： Peter E. Lipsky , Dwain L. Thiele
IPC分类号： A61K38/05
CPC分类号： A61K38/05
摘要： Esters or amides of a peptide, preferably a dipeptide, consisting essentially of natural or synthetic L-amino acids with hydrophobic side chains were found to have specific cellular toxicities. Preferable amino acids of the peptide are leucine, phenylalanine valine, isoleucine, alanine, proline, glycine or aspartic acid beta methyl ester. Preferable dipeptides are L leucyl L-leucine, L-leucyl L-phenylalanine, L-valyl L-phenylalanine, L-leucyl L-isoleucine, L-phenylalanyl L-phenylalanine, L-valyl L-leucine, L-leucyl L-alanine, L-valyl L-valine, L-phenylalanyl L leucine, L prolyl L-leucine, L-leucyl L-valine, L-phenylalanyl L-valine, L glycyl L-leucine, L-leucyl L-glycine, glycyl L-phenylalanine and L-aspartyl beta methyl ester L-phenylalanine. Most preferable dipeptides are L-leucyl L-leucine, L-leucyl L-phenylalanine, L-valyl L-phenylalanine, L-phenylalanyl L-leucine, L-leucyl L-isoleucine L-phenylalanyl L-phenylalanine and L-valyl L-leucine.The ester or amide of the dipeptide is most preferably alkyl, aralkyl or aryl a preferred alkylester is a methyl ester and may also be an ethyl ester or alkyl of up to about four carbon atoms such as propyl, isopropyl, butyl or isobutyl. Yet larger alkyl substituents may also be functional judging from the beta naphthyl substituent which is functional in certain embodiments.These alkyl, aryl or arylkyl esters and amides of dipeptides consist essentially of amino acids with hydrophobic side chains may be used to deplete cytotoxic T-lymphocytes or natural killer cells from organisms, cell populations or tissues.
摘要翻译：被发现具有疏水侧链的天然或合成的L-氨基酸的肽，优选二肽的酯或酰胺具有特异性的细胞毒性。肽的优选氨基酸是亮氨酸，苯丙氨酸缬氨酸，异亮氨酸，丙氨酸，脯氨酸，甘氨酸或天冬氨酸β-甲酯。优选的二肽是L亮氨酸L-亮氨酸，L-亮氨酰L-苯丙氨酸，L-缬氨酰L-苯丙氨酸，L-亮氨酰L-异亮氨酸，L-苯丙氨酰L-苯丙氨酸，L-缬氨酰L-亮氨酸，L-亮氨酰L-丙氨酸，L-缬氨酰L-缬氨酸，L-苯丙氨酰L-亮氨酸，L脯氨酰L-亮氨酸，L-亮氨酰L-缬氨酸，L-苯丙氨酰L-缬氨酸，L-甘氨酰L-亮氨酸，L-亮氨酰L-甘氨酸，苯丙氨酸和L-天冬氨酰基β-甲酯L-苯丙氨酸。最优选的二肽是L-亮氨酸L-亮氨酸，L-亮氨酰L-苯丙氨酸，L-缬氨酰L-苯丙氨酸，L-苯丙氨酰L-亮氨酸，L-亮氨酰L-异亮氨酸L-苯丙氨酰L-苯丙氨酸和L-缬氨酰L- 亮氨酸。二肽的酯或酰胺最优选是烷基，芳烷基或芳基，优选的烷基酯是甲酯，也可以是最多约四个碳原子的乙酯或烷基，如丙基，异丙基，丁基或异丁基。根据在某些实施方案中是功能的β萘基取代基，更大的烷基取代基也可以是官能的。这些二肽的烷基，芳基或芳基烷基酯和酰胺基本上由具有疏水侧链的氨基酸组成可用于从生物体，细胞群或组织中消耗细胞毒性T淋巴细胞或天然杀伤细胞。

9. 发明授权

US4752602A Dipeptide alkyl esters and their uses 失效
标题翻译：二肽烷基酯及其用途
公开(公告)号：US4752602A
公开(公告)日：1988-06-21
申请号：US774051
申请日：1985-09-09
申请人： Peter E. Lipsky , Dwain L. Thiele
发明人： Peter E. Lipsky , Dwain L. Thiele
IPC分类号： A61K38/05 , A61K37/02
CPC分类号： A61K38/05
摘要： An alkyl ester of dipeptide consisting essentially of natural or synthetic L-amino acids with hydrophobic side chains. Preferable amino acids are leucine, phenylalanine valine, isoleucine, alanine, proline, glycine or aspartic acid beta methyl ester. Preferable dipeptides are L leucyl L-leucine, L-leucyl L-phenylalanine, L-valyl L-phenylalanine, L-leucyl L-isoleucine, L-phenylalanyl L-phenylalanine, L-valyl L-leucine, L-leucyl L-alanine, L-valyl L-valine, L-phenylalanyl L leucine, L prolyl L-leucine, L-leucyl L-valine, L-phenylalanyl L-valine, L glycyl L-leucine, L-leucyl L-glycine or L-aspartyl beta methyl ester L-phenylalanine. Most preferable dipeptides are L-leucyl L-leucine, L-leucyl L-phenylalanine, L-valyl L-phenylalanine, L-phenylalanyl L-leucine, L-leucyl L-isoleucine L-phenylalanyl L-phenylalanine and L-valyl L-leucine.The alkyl ester of the dipeptide is most preferably a methyl ester and may also be an ethyl ester or alkyl of up to about four carbon atoms such as propyl, isopropyl, butyl or isobutyl.These alkyl esters of dipeptides consisting essentially of amino acids with hydrophobic side chains may be used to deplete cytotoxic T-lymphocytes or natural killer cells from organisms, cell populations or tissues.
摘要翻译：二肽的烷基酯主要由具有疏水侧链的天然或合成的L-氨基酸组成。优选的氨基酸是亮氨酸，苯丙氨酸缬氨酸，异亮氨酸，丙氨酸，脯氨酸，甘氨酸或天冬氨酸β-甲酯。优选的二肽是L亮氨酸L-亮氨酸，L-亮氨酰L-苯丙氨酸，L-缬氨酰L-苯丙氨酸，L-亮氨酰L-异亮氨酸，L-苯丙氨酰L-苯丙氨酸，L-缬氨酰L-亮氨酸，L-亮氨酰L-丙氨酸，L-缬氨酰L-缬氨酸，L-苯丙氨酰L亮氨酸，L脯氨酰L-亮氨酸，L-亮氨酰L-缬氨酸，L-苯丙氨酰L-缬氨酸，L-甘氨酰L-亮氨酸，L-亮氨酰L-甘氨酸或L-天冬氨酰 β-甲基酯L-苯丙氨酸。最优选的二肽是L-亮氨酸L-亮氨酸，L-亮氨酰L-苯丙氨酸，L-缬氨酰L-苯丙氨酸，L-苯丙氨酰L-亮氨酸，L-亮氨酰L-异亮氨酸L-苯丙氨酰L-苯丙氨酸和L-缬氨酰L- 亮氨酸。二肽的烷基酯最优选是甲酯，也可以是最多约四个碳原子的乙酯或烷基，如丙基，异丙基，丁基或异丁基。这些基本上由具有疏水侧链的氨基酸组成的二肽的烷基酯可用于从生物体，细胞群或组织中消耗细胞毒性T淋巴细胞或天然杀伤细胞。

10. 发明授权

US5500340A Inhibition of IL-2 production by Tripterygium wilfordii Hook F extract 失效
标题翻译：雷公藤提取物对IL-2产生的抑制作用
公开(公告)号：US5500340A
公开(公告)日：1996-03-19
申请号：US136345
申请日：1993-10-14
申请人： Peter E. Lipsky , Xue-Lian Tao
发明人： Peter E. Lipsky , Xue-Lian Tao
IPC分类号： A61K31/365 , A61K31/44 , A61K31/565 , A61K36/00 , A61K36/37 , C12Q1/68 , G01N33/50
CPC分类号： A61K31/565 , A61K31/365 , A61K31/44 , A61K36/37 , Y10S514/885
摘要： The present invention involves the use of Tripterygium Wilfordii Hook F extracts in the treatment of rheumatoid arthritis. An alcohol extract of this plant (T2) inhibited antigen- and mitogen-stimulated proliferation of T cells and B cells, cell cycle progression, interleukin-2 (IL-2) production by T cells, immunoglobulin production by B cells and interleukin-2 mRNA production. T2 did not affect IL-2 receptor expression by T cells, IL-1 production by monocytes, the capacity of monocytes to present antigen, or signaling pathways. Inhibition could not be accounted for by nonspecific toxicity. These results support the conclusion that T2 exerts a powerful suppressive effect on human immune responses. Suppressing autoimmune disease is a most preferred embodiment of this invention.
摘要翻译：本发明涉及使用雷公藤ii钩提取物治疗类风湿性关节炎。该植物的酒精提取物（T2）抑制T细胞和B细胞的抗原和丝裂原刺激的增殖，细胞周期进程，T细胞的白细胞介素-2（IL-2）产生，B细胞的免疫球蛋白产生和白介素-2 mRNA产生。 T2不影响T细胞的IL-2受体表达，单核细胞产生IL-1，单核细胞呈递抗原的能力或信号通路。非特异性毒性不能说明抑制作用。这些结果支持T2对人类免疫应答产生强大的抑制作用的结论。抑制自身免疫疾病是本发明的最优选实施方案。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式